Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A randomized clinical study to evaluate the safety and efficacy of using the Beta 3 agonist
drug (Mirabegron) combined with standard behavioral therapy in comparison to using the
anticholinergic drug (Solifenacin) combined with behavioral therapy, for children with
non-neurogenic voiding dysfunction refractory to behavioral therapy alone, using improvement
of dysfunctional voiding symptom score as a primary measurement of efficacy.